Benjamin Hohl
CHIEF FINANCIAL OFFICER · Enliven Therapeutics, Inc.
- 2024
- Sep 21, 2026
- 18
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Benjamin Hohl files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- ORBIMED ADVISORS LLC - $51.68M in ELVN purchases and sales in the last 12 months
- Mika K. Derynck - $9.56M in ELVN purchases and sales in the last 12 months
- Helen Louise Collins - $5.39M in ELVN purchases and sales in the last 12 months
- Joseph P. Lyssikatos - $4.71M in ELVN purchases and sales in the last 12 months
- Anish Patel - $1.47M in ELVN purchases and sales in the last 12 months
- Lori Anne Kunkel - $850K in ELVN purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Benjamin Hohl?
Benjamin Hohl is a corporate insider, tracked as CHIEF FINANCIAL OFFICER of Enliven Therapeutics, Inc. (ELVN). InsiderAlpha holds 18 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Benjamin Hohl submitted recently?
3 primary Form 4 filings in the last 90 days, covering 1 company.
Has Benjamin Hohl been buying or selling stock?
Recorded transactions: 0 open-market purchases and 33 open-market sales ($2.73M) across all tracked filings.
